Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of UB-221 in Healthy Volunteers (clinicaltrials.gov) - May 18, 2022 - P1 | N=15 | Not yet recruiting | Sponsor: UBP Greater China (Shanghai) Co., Ltd | Trial completion date: Jun 2024 ➔ Jun 2025 | Trial primary completion date: Jun 2022 ➔ Jun 2024
Trial completion date • Trial primary completion date • Chronic Spontaneous Urticaria • Dermatology • Urticaria
|